PAREXEL Strengthens Commitment to Global Biopharmaceutical Workforce
News Apr 10, 2015
PAREXEL International Corporation has announced three new academic programmes at the PAREXEL Academy. The offerings span the globe and are designed to prepare students for careers in the biopharmaceutical industry:
• Bachelor of Science Degree in Clinical Research - Offered in partnership with the Medical School Berlin, in Berlin, Germany, the degree programme features courses specific to clinical research. Courses range from ethics in health and medicine to conducting clinical trials. Several courses are taught by PAREXEL experts.
• Postgraduate Certificate in Clinical Trial Management - In cooperation with Salem State University in Salem, Massachusetts, the postgraduate certificate programme features a broad-based curriculum in various components of the full life cycle of drug development.
• Joint Programme for Clinical Research and Clinical Trial Management - In collaboration with Kyoto Pharmaceutical University in Kyoto, Japan, the joint programme provides fifth grade undergraduate students an introductory, seven-week course in clinical research and clinical trial management.
"PAREXEL is committed to developing the biopharmaceutical industry's next-generation global workforce," said Heidrun Bruchmann, Ph.D., Senior Director, PAREXEL Academy. "Through the PAREXEL Academy, we tailor educational and degree programmes with our partners to equip the future health sciences workforce with a holistic and cross-functional foundation in clinical research and clinical trial management."
For more than a decade, the PAREXEL Academy has designed and implemented a wide range of learning programmes tailored to enable clinical research management practices for learners inside and outside of PAREXEL. The PAREXEL Academy has locations in the United States, Europe, and Asia. Since inception, approximately 1,000 students have graduated from the Academy's programmes, including its undergraduate Bachelor of Science programme.
Mary L. Churchill, Ph.D. Associate Provost, Innovation and Partnerships, Salem State University, commented that "Salem State is committed to providing students with programmes that are both foundational and workforce-aligned. Through our partnership with the PAREXEL Academy, we create programmes to give students the specific tools needed to succeed post-graduation in biopharmaceutical research."
Huntsman Cancer Institute Joins National Clinical Trial Targeting AMLNews
Huntsman Cancer Institute (HCI) at the University of Utah (U of U) has been selected to participate in the Beat AML Master Trial, an innovative clinical trial sponsored by The Leukemia & Lymphoma Society (LLS). The clinical trial is testing several new targeted therapies for the treatment of patients with acute myeloid leukemia (AML). HCI is the only facility in the Mountain West offering this trial to AML patients.READ MORE
Study Extends Potential of Personalized Cell-based ImmunotherapiesNews
New methods developed for the study could be applied to devise personalized, cell-based immunotherapies for epithelial ovarian cancer or other types of tumorsREAD MORE
Hope for Hot Flushes: New Class of Menopause Drugs Reduces SeverityNews
A new class of experimental drugs reduces hot flushes in menopausal women by almost three-quarters in just three days. The new analysis, published in the journal Menopause, also revealed sleep and concentration significantly improved in the three-day window.
Comments | 0 ADD COMMENT
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018
International Conference on Molecular Biology and Stem Cells
Aug 13 - Aug 15, 2018